A. Denkhaus Donald's most recent trade in Catalyst Pharmaceuticals Inc was a trade of 4,000 Common Stock, par value $0.001 per share done . Disclosure was reported to the exchange on Feb. 14, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 495,079 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 158,274 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.24 per share. | 08 Jan 2025 | 50,000 | 491,079 (0%) | 0% | 2.2 | 112,000 | Common Stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2025 | 50,000 | 162,274 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 441,079 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 212,274 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 439,746 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 213,607 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 23,248 | 212,179 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,841 | 215,020 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | A. Donald Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 438,333 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Denkhaus A. Donald | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 188,931 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | A. Donald Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 40,000 | 192,931 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | A. Denkhaus Donald | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 05 Feb 2024 | 40,000 | 434,333 (0%) | 0% | 4.0 | 160,400 | Common Stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald Denkhaus A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 232,931 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | A. Denkhaus Donald | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 394,333 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald Denkhaus A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 29,524 | 230,024 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald Denkhaus A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 4,240 | 234,264 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald Denkhaus A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 60,000 | 200,500 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 03 Aug 2023 | 60,000 | 393,000 (0%) | 0% | 1.1 | 67,800 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 333,000 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 260,500 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 24 Jan 2023 | 50,000 | 329,000 (0%) | 0% | 0.8 | 39,500 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2023 | 50,000 | 264,500 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 15,000 | 310,500 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 4,000 | 314,500 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 279,000 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 295,500 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 11 Nov 2022 | 20,000 | 277,666 (0%) | 0% | 16.6 | 331,880 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Sale of securities on an exchange or to another person at price $ 15.34 per share. | 14 Sep 2022 | 20,000 | 297,666 (0%) | 0% | 15.3 | 306,800 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 12,000 | 296,834 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 40,000 | 284,834 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.53 per share. | 10 Jan 2022 | 40,000 | 317,666 (0%) | 0% | 2.5 | 101,200 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2022 | 50,000 | 324,834 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 05 Jan 2022 | 50,000 | 277,666 (0%) | 0% | 3.4 | 167,500 | Common stock, par value $0.001 per share |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2021 | 20,000 | 374,834 | - | - | Options to purchase common stock | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 354,834 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 227,666 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 326,167 | - | - | Restricted Stock Units | |
Catalyst Pharmaceuticals Inc | Donald A. Denkhaus | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 226,333 (0%) | 0% | - | Common Stock, par value $0.001 per share |